Vibecotamab
Based on 1 Customer Validation
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.34%
- CAS No.: 2138442-13-2
- Masse moléculaire:126.15 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Isotype
half-IGG1-kappa/(scFv-heavy-lambda)-h-CH2-CH3
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD3E & IL3RA
In Vitro
Vibecotamb (Compound XmAb14045) stimulates T cell-mediated killing of CD123+ KG-1a and TF-1 AML cell lines (EC50 = 8 pM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Vibecotamb (0.01-1 mg/kg, single dose) strongly activates T cells and stimulates depletion of over 99% of circulating CD123+ cells including basophils and plasmacytoid dendritic cells within 1 h of administration in cynomolgus monkey[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Vibecotamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC50 for this effect is 0.48 ng/mL. -
Immobilized Vibecotamab can bind Human IL-3R alpha/CD123 Protein (ECD, His Tag). The EC50 for this effect is 7.66 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Vibecotamab (HY-P99521). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2138442-13-2
-
Appearance Liquid
-
Masse moléculaire 126.15 kDa
-
Color Colorless to light yellow
-
SMILES
[Vibecotamab]
-
Synonyms
XmAb14045
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Pureté et documentation
-
Fiche technique (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)